AU5134799A - 98 human secreted proteins - Google Patents

98 human secreted proteins

Info

Publication number
AU5134799A
AU5134799A AU51347/99A AU5134799A AU5134799A AU 5134799 A AU5134799 A AU 5134799A AU 51347/99 A AU51347/99 A AU 51347/99A AU 5134799 A AU5134799 A AU 5134799A AU 5134799 A AU5134799 A AU 5134799A
Authority
AU
Australia
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51347/99A
Other languages
English (en)
Inventor
Laurie A. Brewer
Roxanne Duan
Reinhard Ebner
Gregory A. Endress
Kimberly A. Florence
George A. Komatsoulis
David Lafleur
Paul A Moore
Michael Mucenski
Jian Ni
Henrik S. Olsen
Craig A Rosen
Steven M. Ruben
Yanggu Shi
Daniel R Soppet
Ying-Fei Wei
Paul E. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU5134799A publication Critical patent/AU5134799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
AU51347/99A 1998-07-30 1999-07-29 98 human secreted proteins Abandoned AU5134799A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US9465798P 1998-07-30 1998-07-30
US60094657 1998-07-30
US9548698P 1998-08-05 1998-08-05
US60095486 1998-08-05
US9545598P 1998-08-06 1998-08-06
US9545498P 1998-08-06 1998-08-06
US60095455 1998-08-06
US60095454 1998-08-06
US9631998P 1998-08-12 1998-08-12
US60096319 1998-08-12
PCT/US1999/017130 WO2000006698A1 (en) 1998-07-30 1999-07-29 98 human secreted proteins

Publications (1)

Publication Number Publication Date
AU5134799A true AU5134799A (en) 2000-02-21

Family

ID=27536719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51347/99A Abandoned AU5134799A (en) 1998-07-30 1999-07-29 98 human secreted proteins

Country Status (6)

Country Link
US (3) US6476195B1 (https=)
EP (1) EP1100869A4 (https=)
JP (1) JP2002521055A (https=)
AU (1) AU5134799A (https=)
CA (1) CA2339301A1 (https=)
WO (1) WO2000006698A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030022293A1 (en) * 1997-09-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030049751A1 (en) * 1997-09-18 2003-03-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7196165B2 (en) * 1997-10-17 2007-03-27 Genentech, Inc. PRO363 polypeptides
US7067636B2 (en) * 1998-05-06 2006-06-27 Genentech, Inc. Anti-pro 1017 antibodies
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2003204365B2 (en) * 1998-09-01 2006-09-07 Genentech, Inc. Further pro polypeptides and sequences thereof
US7414112B2 (en) * 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
WO2000039296A1 (en) 1998-12-23 2000-07-06 Immunex Corporation Lectin s3939 dna and polypeptides
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU4462600A (en) * 1999-04-12 2000-11-14 Agensys, Inc. Novel prostate-restricted gene expressed in prostate cancer
MXPA01011519A (es) * 1999-05-13 2003-08-20 Medical Res Council Homologos del receptor ox2.
WO2000071581A1 (fr) * 1999-05-20 2000-11-30 Takeda Chemical Industries, Ltd. Nouveau polypeptide
AU5037100A (en) * 1999-05-27 2000-12-18 Zymogenetics Inc. Adipocyte complement related protein homolog zacrp6
US20030022279A1 (en) 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
PT1200590E (pt) 1999-08-12 2009-03-24 Agensys Inc Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
AUPQ272899A0 (en) * 1999-09-09 1999-09-30 Csl Limited Dendritic cell membrane protein fire
WO2001036466A2 (en) * 1999-11-19 2001-05-25 Zymogenetics, Inc. Educational kit and method using colipase-like protein-1
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
EP2298333A3 (en) 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
JP2004500816A (ja) * 2000-01-14 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド 薬剤代謝酵素
US20040086854A1 (en) * 2001-01-12 2004-05-06 Junming Yang Drug metabolizing enzymes
US20020068710A1 (en) * 2000-02-29 2002-06-06 Millennium Pharmaceuticals, Inc. 20685, 579, 17114, 23821, 33894 and 32613, novel human transporters
US7390634B2 (en) 2000-02-29 2008-06-24 The General Hospital Corporation β-netrin and uses thereof
DE10027383A1 (de) * 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
ATE412009T1 (de) * 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7186818B2 (en) * 2001-04-26 2007-03-06 Immunex Corporation DNA encoding soluble variants of human OX2 receptors
US20030068636A1 (en) * 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
EP1436392A2 (en) * 2001-07-26 2004-07-14 Genset S.A. Gmg-2 polynucleotides and polypeptides and uses thereof
EP1442046A4 (en) * 2001-10-09 2005-08-31 Immunex Corp MAMMALIAN TYPE C LECTINES
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
DE20202893U1 (de) * 2002-02-25 2003-07-03 Sachsenring Fahrzeugtechnik Gm Vorrichtung zur Lagerung einer Kolbenverdichterbaugruppe
NZ553470A (en) * 2002-03-15 2008-10-31 Schering Corp Methods of modulating CD200 receptors
US20040018976A1 (en) * 2002-05-14 2004-01-29 Feder John N. Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US20060121471A1 (en) * 2002-08-14 2006-06-08 L G Life Sciences Ltd. Gene families associated with stomach cancer
DE10242146A1 (de) 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
WO2004052186A2 (en) * 2002-12-11 2004-06-24 The Forsyth Institute Expressed genes that define the osteoclast phenotype
CN100422328C (zh) * 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135
DE602004006871T2 (de) 2003-07-24 2008-02-07 Amgen Inc., Thousand Oaks Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
EP1691820A4 (en) 2003-11-08 2010-03-03 Prothera Biolog PREPARATION AND COMPOSITION OF INTER ALPHA HEMMER PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CN106928346B (zh) 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
WO2010068308A1 (en) * 2008-12-10 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
CN109789193A (zh) 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
EP3615937B1 (en) 2017-04-25 2026-01-28 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CN109324189B (zh) * 2018-08-15 2021-10-01 泰达国际心血管病医院 多蛋白组合物的应用及先天性心脏病筛查试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543252A (en) * 1982-01-21 1985-09-24 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
US5091303A (en) * 1989-10-27 1992-02-25 The General Hospital Corporation Diagnosis of wegener's granulomatosis
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US5837490A (en) * 1996-06-17 1998-11-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5827688A (en) * 1996-06-17 1998-10-27 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5807703A (en) * 1996-06-17 1998-09-15 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP2001502906A (ja) * 1996-10-25 2001-03-06 セダーズ―シナイ メディカル センター Ｄｓ―ｃａｍタンパク質をコードする核酸およびそれに関連する産物
US5843727A (en) * 1997-04-08 1998-12-01 Incyte Pharmacuticals, Inc. Polynucleotides encoding a human tumor-associated membrane protein

Also Published As

Publication number Publication date
JP2002521055A (ja) 2002-07-16
US6476195B1 (en) 2002-11-05
US20080051338A1 (en) 2008-02-28
CA2339301A1 (en) 2000-02-10
US20060079670A1 (en) 2006-04-13
EP1100869A1 (en) 2001-05-23
WO2000006698A1 (en) 2000-02-10
EP1100869A4 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
AU4682999A (en) 94 human secreted proteins
AU5134799A (en) 98 human secreted proteins
AU2577799A (en) 45 human secreted proteins
AU5583799A (en) 49 human secreted proteins
AU6552198A (en) 28 human secreted proteins
AU2306499A (en) 110 human secreted proteins
AU4010400A (en) 27 human secreted proteins
AU3124000A (en) 47 human secreted proteins
AU6952998A (en) 20 human secreted proteins
AU2471899A (en) 67 human secreted proteins
AU1438001A (en) 27 human secreted proteins
AU2451199A (en) 36 human secreted proteins
AU8066998A (en) 86 human secreted proteins
AU9130498A (en) 50 human secreted proteins
AU5212299A (en) 71 human secreted proteins
AU5928899A (en) 31 human secreted proteins
AU1334101A (en) 19 human secreted proteins
AU1231400A (en) 12 human secreted proteins
AU5591200A (en) 49 human secreted proteins
AU8404598A (en) 64 human secreted proteins
AU3006799A (en) 31 human secreted proteins
AU5457000A (en) 48 human secreted proteins
AU1273499A (en) 148 human secreted proteins
AU8921598A (en) 29 human secreted proteins
AU1342501A (en) 32 human secreted proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase